CRISPR Therapeutics AG (CRSP) EBIAT (2016 - 2025)
CRISPR Therapeutics AG (CRSP) has disclosed EBIAT for 11 consecutive years, with -$130.6 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 250.07% to -$130.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$581.6 million through Dec 2025, down 58.8% year-over-year, with the annual reading at -$581.6 million for FY2025, 58.8% down from the prior year.
- EBIAT hit -$130.6 million in Q4 2025 for CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $759.2 million in Q2 2021 to a low of -$208.5 million in Q2 2025.
- Historically, EBIAT has averaged -$68.7 million across 5 years, with a median of -$114.9 million in 2021.
- Biggest five-year swings in EBIAT: surged 1053.13% in 2021 and later tumbled 250.07% in 2025.
- Year by year, EBIAT stood at -$141.2 million in 2021, then grew by 21.72% to -$110.6 million in 2022, then skyrocketed by 180.8% to $89.3 million in 2023, then plummeted by 141.76% to -$37.3 million in 2024, then crashed by 250.07% to -$130.6 million in 2025.
- Business Quant data shows EBIAT for CRSP at -$130.6 million in Q4 2025, -$106.4 million in Q3 2025, and -$208.5 million in Q2 2025.